Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

Clene plans CNM-Au8 filing for accelerated approval in ALS

Original source

Clene plans CNM-Au8 filing for accelerated approval in ALSBioNews, Inc. · 5 May 2026

Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.

Clene plans to file for accelerated approval of CNM-Au8 in amyotrophic lateral sclerosis (ALS).

Why this matters

The planned filing could lead to regulatory review of CNM-Au8 for ALS, but it does not establish that the treatment is approved or available.

Limitations and context

This is based only on the title and metadata of an ALS News Today report, not the article text or a primary research publication. The timing, supporting evidence and regulatory status are not available from the supplied source.

Relevant to you?